Trial Profile
A randomized phase III study of maintenance therapy with TS-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus TS-1 for advanced or relapsed squamous cell carcinoma of the lung
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Carboplatin
- Indications Adenocarcinoma; Adenosquamous carcinoma; Lung cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 02 Jun 2020 Status changed to discontinued.
- 02 Jun 2020 Results published in the Cancer.
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer.